A decade ago, walking into an Indian hospital meant seeing shelves and machines stamped with foreign labels. MRI scanners from Europe, cardiac stents from the US, even syringes imported from China. India’s healthcare backbone was largely built abroad.
Fast forward to 2025, and the story is very different. India’s medical devices market has grown into an $11.2 billion industry, expanding at 11% annually. Domestic manufacturing is rising, investor money is flowing in, and policies are nudging the ecosystem toward self-reliance.
But where exactly is this growth happening? And more importantly, where are the gaps still waiting to be filled?
o3 Capital’s recent report, Healthcare Primer – Medical Devices (August 2025), maps this transformation in detail.
Here’s the breakdown for you.
Clearing the jargon
Before diving in, the report does something refreshingly simple. It clears up the terminology confusion.
While “med-tech,” “medical products,” and “medical devices” are often used interchangeably, they are not the same.
- Medical products is a broad WHO category that includes drugs, biologics, and devices.
- Med-tech is loosely used in industry to describe any tech-enabled healthcare product or service.
- Medical devices are precisely defined by regulators such as WHO, EU-MDR, and the US FDA as instruments, implants, reagents, or software for diagnosis, monitoring, or treatment (but not drugs or biologics.
The report argues that “medical devices” is the most accurate term in India’s context. And that clarity is the key to shaping how regulation, funding, market positioning, and growth are framed.
8 key segments shaping India’s medical devices market
The report breaks down the market into eight major segments, highlighting both size and growth prospects (2025 estimates):
- In-Vitro Diagnostics (IVD): $2.2B, 13% CAGR. Includes immunoassay, biochemistry, hematology, PoC, and molecular testing.
- Imaging & Critical Care: $2.2B, 10% CAGR. Includes ultrasound, MRI, CT, X-ray, PET, and endoscopy.
- Interventional Products: $1.7B, 13% CAGR. Includes cardiac products, orthopedic implants, and sutures.
- Consumables: $1.5B, 11% CAGR. Includes syringes, needles, gloves, and related items.
- B2C Products: $1.3B, 10% CAGR. Includes wound care, glucometers, and mobility aids.
- Ophthalmic Instruments: $1.3B, 5% CAGR. Includes vision care, diagnostic, and surgical devices.
- Dental Products: $0.5B, 7% CAGR. Includes instruments, teeth and fittings, cements.
- Others: $0.5B, 8% CAGR. Includes patient aids, hospital furniture, dialysis, sterilizers.
Two things stand out:
#1 IVD and imaging are the largest segments, while interventional and IVD are the fastest growing.
#2 Growth is not uniform. Ophthalmic and dental show relatively slower expansion, signaling niche but steady opportunities.
How businesses operate
Each segment is shaped by different business levers:
- Consumables compete on price, with low differentiation.
- Interventional products depend on clinical evidence, regulatory approvals, and physician adoption.
- Imaging companies differentiate on machine uptime, service quality, and throughput.
- IVD firms succeed through test throughput, cost per test, and range of assays.
- B2C products rely on distribution reach and brand trust.
- Ophthalmic and dental segments depend on quality, bundling, and customization.
The margin structure reflects these differences. IVD enjoys high margins due to IP intensity and automation, while consumables remain volume-driven with thinner profitability.
Investment and deal flow
Here’s where things get interesting.
Despite the industry’s size, public market activity is limited. Only five transactions across four listed companies in the past decade. This underlines how underpenetrated the listed space remains.
But behind the scenes, private equity and M&A tell a different story:
- Consumables and interventional devices are hotbeds of consolidation.
- Private equity is zeroing in on interventional devices, supported by policies that reward local manufacturing.
- Landmark deals: KKR India’s $810M bet on Healthium Medtech (2024), ADIA’s $200M into Meril (2025).
Meanwhile, B2C, ophthalmic, and dental devices remain highly fragmented. Too few scaled players to attract big-ticket action.
The white spaces nobody is talking about
This is perhaps the report’s sharpest insight. The real opportunity lies in the unfunded and fragmented segments.
- IVD and consumables: large pools of unfunded companies, presenting attractive entry points for private equity.
- Ophthalmic and dental devices: highly fragmented revenues, creating scope for consolidation.
This highlights a dual opportunity:
- Investors can back high-growth, underfunded players in IVD.
- Strategic buyers can roll up fragmented niches in ophthalmic and dental to build scale.
India’s big moment
So, where does this leave us?
India’s medical devices market is no longer an import story. It’s a domestic capability story. Policy support, capital inflows, and local ambition have all created momentum.
But the next chapter won’t be written by funding alone. The real test lies in building reliable local manufacturing, setting uncompromising quality benchmarks, and breaking into global markets.
Because the question isn’t just whether India can become self-sufficient in devices.
The real question is: Can India become a global leader in medtech innovation?
-By Rinkle Dudhani and the AHT Team
